Bowen Acquisition CORP 8-K filings

Bowen Acquisition Corp shareholders approved an amendment to extend the deadline for completing its initial business combination until June 14, 2026.

Bowen Acquisition Corp. received a delisting notice from Nasdaq after failing to meet listing standards and complete its business combination by the October 15, 2025 deadline.

Bowen Acquisition Corp has received a delisting determination from Nasdaq due to failure to meet multiple listing standards, including minimum shareholder count and market value requirements, leading to a trading halt.

Bowen Acquisition Corp shareholders approved an amendment to the company's articles of association, allowing the board to extend the deadline for completing its initial business combination until December 14, 2025.

Bowen Acquisition Corp received a notice from Nasdaq regarding its failure to maintain the minimum required publicly held shares, necessitating a compliance plan submission by August 25, 2025.

Bowen Acquisition Corp announced a second amendment to its merger agreement with Shenzhen Qianzhi BioTechnology Co. Ltd. and Qianzhi Group Holding (Cayman) Limited, extending the outside date for consummation to December 14, 2025.

Bowen Acquisition Corp, a SPAC, has received a non-compliance notice from NASDAQ for failing to timely file its quarterly report, potentially jeopardizing its listing.

Bowen Acquisition Corp. gains shareholder approval to extend the deadline for completing its initial business combination by up to three months, now potentially extending to July 14, 2025.

Bowen Acquisition Corp. has amended its merger agreement with Shenzhen Qianzhi BioTechnology, extending the deadline for completion to July 14, 2025.

Bowen Acquisition Corp. received a notice from Nasdaq on March 19, 2025, indicating that its ordinary shares' market value had fallen below the $50 million minimum required for continued listing, granting the company until September 15, 2025, to regain compliance.

Bowen Acquisition Corp. announces shareholder approval of its business combination with Qianzhi Group Holding and Shenzhen Qianzhi BioTech Company Limited at an extraordinary general meeting held on January 13 and 14, 2025.

Bowen Acquisition Corp secures a Prepaid Forward Purchase Agreement to potentially maximize funds retained after its business combination with Qianzhi Group Holding.

Bowen Acquisition Corp. successfully obtained shareholder approval to extend the deadline for completing a business combination by up to three months, now potentially reaching April 14, 2025.

Bowen Acquisition Corp has adjourned its extraordinary general meeting to January 10, 2025, to allow more time to solicit votes for a proposal to extend the deadline for completing a business combination.

Bowen Acquisition Corp clarifies the share redemption process for shareholders ahead of meetings to approve a business combination and a potential extension to the deadline for the deal.

Bowen Acquisition Corp has entered into a subscription agreement to raise $5 million through a private placement of ordinary shares, contingent on the completion of its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp received a $690,000 loan to extend the deadline for its initial business combination to January 14, 2025.

Bowen Acquisition Corp has agreed to a merger with Shenzhen Qianzhi BioTech, a Chinese biotech company focused on ozonated health and wellness products.